Paul Soo Chye Goh

Paul Soo Chye Goh

Auto-generated profile, based on publicly available information

Paul Soo Chye Goh

SingHealth Polyclinics, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
DKDavid Koot
David Koot
PGPaul Soo Chye Goh
Paul Soo Chye Goh
RLRobyn Su May Lim
Robyn Su May Lim
YTYubing Tian
Yubing Tian
TYTeng Yan Yau
Teng Yan Yau
EFEric Finkelstein
Eric Finkelstein
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Singapore’s current prevalence of diabetes exceeds 13.6%. Although lifestyle modification can be effective at reducing the risks for complications of Type 2 Diabetes Mellitus (T2DM), traditional lifestyle interventions are often difficult to administer in the primary care setting due to limited resources. Mobile health applications can address these limitations by offering low-cost, adaptable, and accessible platforms for disseminating lifestyle management interventions. Objective: Using the RE-AIM evaluation framework, this study assesses the potential effectiveness and feasibility of GlycoLeap, a mobile lifestyle management program for people with T2DM, as an add-on to standard care. Methods: This single-arm feasibility study recruited 100 patients with T2DM and glycosylated hemoglobin (HbA1c) levels of ≥7.5% from a single community healthcare facility in Singapore. All participants were given access to a 6-month mobile lifestyle management program, GlycoLeap, comprising online lessons and the Glyco smartphone app with a health coaching feature. The GlycoLeap program was evaluated using four relevant dimensions of the RE-AIM framework: (1) Reach (percentage who consented to participate out of all patients approached), (2) Effectiveness (percentage point change in HbA1c [primary outcome] and weight loss [secondary outcome]), (3) Implementation (program engagement as assessed by various participatory metrics), and (4) Maintenance (post-intervention user satisfaction surveys to predict the sustainability of GlycoLeap). Participants were assessed at baseline and at follow-up (≥12 weeks after starting the intervention). Results: A total of 785 patients were approached of which 104 consented to participate, placing the Reach at 13.2%. Four were excluded after eligibility screening and 100 patients were recruited. Program engagement (Implementation) started out high but decreased with time for all evaluated components. Self-reported survey data suggest that participants monitored their blood glucose on more days in the past week at follow-up compared to baseline (P<.001) and reported positive changes to their diet due to app engagement (P<.001) (Implementation). Primary outcome data was available for 83 participants. Statistically significant improvements were observed for HbA1c (-1.3 percentage points, P<.001) with greater improvements for those who logged their weight more often (P=.007) (Effectiveness). Participants also had a 2.3% reduction in baseline weight (P<.001) (Effectiveness). User satisfaction was high with 59 (74%) and 63 (79%) out of 80 participants rating the app “good/very good” and claiming that they “would probably/definitely recommend” the app to others, respectively (Maintenance). Conclusions: Although measures of program engagement decreased with time, clinically significant improvements in HbA1c were achieved and with the potential for broader implementation. However, we cannot rule out that these improvements were due to factors unrelated to GlycoLeap. Therefore, we would recommend evaluating the effectiveness and cost-effectiveness of GlycoLeap using a randomized controlled trial of at least 12 months. Clinical Trial: The study is registered on ClinicalTrials.gov (www.clinicaltrials.gov) with the identifier NCT03091517.

1 January 2024 in Proceedings of Singapore Healthcare
Verified
Journal Article
Open access
SFSharon Siew May Fan
Sharon Siew May Fan
DKDavid Koot
David Koot
BCBoon Ming Chua
Boon Ming Chua
JSJun Hao Shu
Jun Hao Shu
ASAi Choo Seah
Ai Choo Seah
PGPaul Soo Chye Goh
Paul Soo Chye Goh
Background: HbA1c test is the most-ordered laboratory test in public primary care clinics, accounting for 17% of laboratory services. In recent years, there has been growing adoption of self-service technology in taking clinical measurements. However, there are currently no on-site self-testing HbA1c facilities. This study assessed patients’ acceptability and ability to perform self-testing of HbA1c levels and the feasibility of implementation in primary care setting. Methods: A total of 30 eligible diabetic patients were recruited in Tampines Polyclinic. Participants were shown a demonstration video before self-testing with a Point-of-Care HbA1c analyzer and completed a questionnaire after self-testing. The usability of the system was assessed using System Usability Scale (SUS). Acceptance and ability were assessed using either a five or six point-Likert Scale for the 7-step procedure. Fisher’s exact test was used to test for association with SUS score. Results: The study population comprises mainly males (60.0%), Chinese (50.0%), had highest qualification of secondary education and beyond (80.0%), with a mean age of 61.4 ± 8.3 years. The mean SUS score was 66.5 ± 13.3 and the average time taken to complete the HbA1c self-testing was 11.8 ± 4.5 min. No significant association was observed between demographics and SUS score. Although 40.0% of participants experienced some difficulty in inserting the cartridge into the analyzer, all were able to understand and follow the video and were willing to perform self-testing in the future. Conclusion: There is high level of acceptance and ability among diabetic patients to adopt HbA1c self-testing. It is feasible for use in primary care.

28 November 2018 in JMIR Preprints
Verified
Preprint
Open access
DKDavid Koot
David Koot
PGPaul Soo Chye Goh
Paul Soo Chye Goh
RLRobyn Su May Lim
Robyn Su May Lim
YTYubing Tian
Yubing Tian
TYTeng Yan Yau
Teng Yan Yau
EFEric Finkelstein
Eric Finkelstein
BACKGROUND Singapore’s current prevalence of diabetes exceeds 13.6%. Although lifestyle modification can be effective for reducing the risks for complications of type 2 diabetes mellitus (T2DM), traditional lifestyle interventions are often difficult to administer in the primary care setting due to limited resources. Mobile health apps can address these limitations by offering low-cost, adaptable, and accessible platforms for disseminating lifestyle management interventions. OBJECTIVE Using the RE-AIM evaluation framework, this study assessed the potential effectiveness and feasibility of GlycoLeap, a mobile lifestyle management program for people with T2DM, as an add-on to standard care. METHODS This single-arm feasibility study recruited 100 patients with T2DM and glycated hemoglobin (HbA1c) levels of ≥7.5% from a single community health care facility in Singapore. All participants were given access to a 6-month mobile lifestyle management program, GlycoLeap, comprising online lessons and the Glyco mobile phone app with a health coaching feature. The GlycoLeap program was evaluated using 4 relevant dimensions of the RE-AIM framework: (1) reach (percentage who consented to participate out of all patients approached), (2) effectiveness (percentage point change in HbA1c [primary outcome] and weight loss [secondary outcome]), (3) implementation (program engagement as assessed by various participatory metrics), and (4) maintenance (postintervention user satisfaction surveys to predict the sustainability of GlycoLeap). Participants were assessed at baseline and at follow-up (≥12 weeks after starting the intervention). RESULTS A total of 785 patients were approached of whom 104 consented to participate, placing the reach at 13.2%. Four were excluded after eligibility screening, and 100 patients were recruited. Program engagement (implementation) started out high but decreased with time for all evaluated components. Self-reported survey data suggest that participants monitored their blood glucose on more days in the past week at follow-up compared to baseline (P<.001) and reported positive changes to their diet due to app engagement (P<.001) (implementation). Primary outcome data were available for 83 participants. Statistically significant improvements were observed for HbA1c (–1.3 percentage points, P<.001) with greater improvements for those who logged their weight more often (P=.007) (effectiveness). Participants also had a 2.3% reduction in baseline weight (P<.001) (effectiveness). User satisfaction was high with 74% (59/80) and 79% (63/80) of participants rating the app good or very good and claiming that they would probably or definitely recommend the app to others, respectively (maintenance). CONCLUSIONS Although measures of program engagement decreased with time, clinically significant improvements in HbA1c were achieved with the potential for broader implementation. However, we cannot rule out that these improvements were due to factors unrelated to GlycoLeap. Therefore, we would recommend evaluating the effectiveness and cost effectiveness of GlycoLeap using a randomized controlled trial of at least 12 months. CLINICALTRIAL ClinicalTrials.gov NCT03091517; https://clinicaltrials.gov/ct2/show/NCT03091517 (Archived by WebCite at http://www.webcitation.org/77rNqhwRn)